Research analysts at Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a report issued on Wednesday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.
Palvella Therapeutics Stock Performance
PVLA opened at $13.00 on Wednesday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- How to Use Stock Screeners to Find Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Is Lucid Group’s Stock a Recovery Play or a Risky Bet?
- Stock Market Upgrades: What Are They?
- Top 3 Aerospace and Defense Stocks Flying Under the Radar
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
